CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Larry Zhang - President Alexander Zukiwski - Executive Vice President and Chief Medical Officer James Goldschmidt - Chief Business Development Officer Conference Call Participants Justin Zelin - BTIG Sean Lee - HC Wainwright Trevor Allred - Oppenheimer Operator Good morning everyone and welcome to the CASI Pharmaceutical ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q4 2021 Earnings Conference Call March 28, 2022 8:00 AM ET Company Participants Wei-Wu He - Chairman and Chief Executive Officer Wei Zhang - President Alex Zukiwski - Chief Medical Officer Jim Goldschmidt - Senior Vice President, Business Development Conference Call Participants Leland Gershell - Oppenheimer Sean Lee - H.C. Wainwright Justin Zelin - BTIG Operator Good morning and welcome to the CASI Pharmaceuticals Year End 2021 Conference Call. [Operator Instruction ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q3 2021 Earnings Conference Call November 12, 2021 8:00 AM ET Company Participants Jacob Moshel - IR Wei-Wu He - Chairman & CEO Alexander Zukiwski - Chief Medical Officer Wong Hu - Former COO, General Counsel & Secretary Conference Call Participants Leland Gershell - Oppenheimer Sean Lee - H.C. Wainwright & Co. Justin Zelin - BTIG Operator Hello and welcome to the CASI Pharmaceuticals, announced Third Quarter 2021 Financial Results. [Operator Instructions]. Today's e ...

Financial Data and Key Metrics Changes - CASI Pharmaceuticals reported revenues of $7.1 million for EVOMELA in Q2 2021, representing a 173% increase compared to the same quarter last year [7][17] - The company revised its revenue growth guidance for 2021 to exceed 80% over 2020 based on current trends [7][17] - Cash and cash equivalents as of June 30, 2021, were $60.4 million, up from $57.1 million at the end of 2020, indicating sufficient resources to fund operations beyond 2022 [17] Business Line Data and Key Metrics Changes - EVOMELA is the only injectable melphalan commercially available in China, and its revenue growth is attributed to increased market awareness and adaptation [7][8] - The cost of revenues for Q2 2021 was $2.9 million, compared to $2.5 million in Q2 2020, with a significant decrease in cost of revenues as a percentage of revenues due to improved manufacturing processes [17] Market Data and Key Metrics Changes - The Chinese pharmaceutical market is characterized by rapid growth and innovation, driven by a large patient population and recent government reforms [6] - The approval of CAR-T therapies in China is expected to evolve the commercial market, with CASI positioned to offer a domestically produced CAR-T 19 therapy at a lower cost than imported alternatives [26][27] Company Strategy and Development Direction - CASI aims to build a major integrated biopharmaceutical company using China as its foundation, focusing on launching products and acquiring assets [18] - The company is expanding its commercial team and strengthening its R&D capabilities to support the launch of new products, including CAR-T 19 and BI-1206 [18][30] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's financial performance and the potential for continued revenue growth, particularly for EVOMELA and upcoming products [5][18] - The company is focused on addressing patient needs and believes that its innovative products will provide significant benefits in the Chinese market [49][50] Other Important Information - The company has established a commercial group of over 100 specialists in hematology and oncology in China, enhancing its market access and collaboration with key opinion leaders [9] - CASI's product pipeline includes several promising assets, such as BI-1206 and CB-5339, which are in various stages of clinical development [12][14] Q&A Session Summary Question: Was there any pull-through from Q1 seasonality with Q2 results? - Management expects quarter-to-quarter growth and believes that the unique market conditions in China will support continued revenue increases [22][23] Question: What are the expectations for CID-103 based on enrollment? - Currently, there are 3 active sites in France and the U.K., with plans to expand to additional sites [24] Question: How does CASI view the evolving commercial market for cell therapy in China? - Management is excited about the first CAR-T approval in China and believes that their domestically produced CAR-T 19 will have a competitive advantage due to lower costs [26][27] Question: What are the next steps in the regulatory process for CNCT19? - The company plans to complete Phase II patient data and expects to submit an NDA to the NMPA by the end of the year or early next year [29][30] Question: What are the clinical plans for BI-1206? - CASI intends to submit an IND in China for relapsed and refractory non-Hodgkin's lymphoma by the end of 2021, leveraging data from BioInvent's global trials [36]

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q1 2021 Earnings Conference Call May 13, 2021 8:00 AM ET Company Participants Cynthia Hu - General Counsel & Secretary Dr. Wei-Wu He - Chairman & Chief Executive Officer Larry Zhang - President Dr. Alex Zukiwski - Chief Medical Officer Conference Call Participants Trevor Allred - Oppenheimer Difei Yang - Mizuho Securities Justin Zelin - B. Riley Securities Sean Lee - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to CASI Pharmaceuticals Fi ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Cynthia Hu - General Counsel & Secretary Wei-Wu He - Chairman & Chief Executive Officer Alex Zukiwski - Chief Medical Officer Jim Goldschmidt - Senior Vice President Conference Call Participants Sean Lee - HC Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the CASI Pharmaceuticals Third Quarter Financial Results and Business Update Conference Call. At this time, ...

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Q2 2020 Results Conference Call August 10, 2020 4:30 PM ET Company Participants Cynthia Hu - General Counsel & Secretary Dr. Wei-Wu He - Chairman and CEO Dr. Alex Zukiwski - Chief Medical Officer Conference Call Participants Nathaniel Calloway - Edison Group Sean Lee - HC Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to CASI Pharmaceuticals Second Quarter Financial Results and Business Update Conference Call. At this time, all participants hav ...